Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel clinical brain prognostic index for KRAS-mutated lung cancer and brain metastases (KRAS-BPI): Real-world evidence from two large European centers.
Zerdes I, Kamali C, Johannsdottir B, Blasi M, Assmann C, Kazdal D, Stenzinger A, Skribek M, Ekman S, Christopoulos P, Tsakonas G. Zerdes I, et al. Among authors: kazdal d. Lung Cancer. 2024 Dec 17;199:108065. doi: 10.1016/j.lungcan.2024.108065. Online ahead of print. Lung Cancer. 2024. PMID: 39705826 Free article.
Clinical Implementation of a High-Throughput Automated Comprehensive Genomic Profiling Test: TruSight Oncology 500 HT.
Ball M, Romanovsky E, Schnecko F, Kirchner M, Neumann O, Brandt R, Beck S, Seker-Cin H, Kluck K, Ourailidis I, Goldschmid H, Fink A, Volckmar AL, Menzel M, Allgäuer M, Schirmacher P, Budczies J, Stenzinger A, Kazdal D. Ball M, et al. Among authors: kazdal d. J Mol Diagn. 2024 Dec 12:S1525-1578(24)00305-2. doi: 10.1016/j.jmoldx.2024.11.005. Online ahead of print. J Mol Diagn. 2024. PMID: 39674366 Free article.
Pathology in the legal framework of European and German medical device law: Operation, use and in-house manufacture of in vitro diagnostic medical devices.
Kahles A, Goldschmid H, Volckmar AL, Kazdal D, Gassner UM, Vogeser M, Brüggemann M, Bürrig KF, Kääb-Sanyal V, Flechtenmacher C, Schirmacher P, Stenzinger A. Kahles A, et al. Among authors: kazdal d. Ger Med Sci. 2024 Oct 11;22:Doc09. doi: 10.3205/000335. eCollection 2024. Ger Med Sci. 2024. PMID: 39559338 Free PMC article. Review.
Benchmarking whole exome sequencing in the German network for personalized medicine.
Menzel M, Martis-Thiele M, Goldschmid H, Ott A, Romanovsky E, Siemanowski-Hrach J, Seillier L, Brüchle NO, Maurer A, Lehmann KV, Begemann M, Elbracht M, Meyer R, Dintner S, Claus R, Meier-Kolthoff JP, Blanc E, Möbs M, Joosten M, Benary M, Basitta P, Hölscher F, Tischler V, Groß T, Kutz O, Prause R, William D, Horny K, Goering W, Sivalingam S, Borkhardt A, Blank C, Junk SV, Yasin L, Moskalev EA, Carta MG, Ferrazzi F, Tögel L, Wolter S, Adam E, Matysiak U, Rosenthal T, Dönitz J, Lehmann U, Schmidt G, Bartels S, Hofmann W, Hirsch S, Dikow N, Göbel K, Banan R, Hamelmann S, Fink A, Ball M, Neumann O, Rehker J, Kloth M, Murtagh J, Hartmann N, Jurmeister P, Mock A, Kumbrink J, Jung A, Mayr EM, Jacob A, Trautmann M, Kirmse S, Falkenberg K, Ruckert C, Hirsch D, Immel A, Dietmaier W, Haack T, Marienfeld R, Fürstberger A, Niewöhner J, Gerstenmaier U, Eberhardt T, Greif PA, Appenzeller S, Maurus K, Doll J, Jelting Y, Jonigk D, Märkl B, Beule D, Horst D, Wulf AL, Aust D, Werner M, Reuter-Jessen K, Ströbel P, Auber B, Sahm F, Merkelbach-Bruse S, Siebolts U, Roth W, Lassmann S, Klauschen F, Gaisa NT, Weichert W, Evert M, Armeanu-Ebinger S, Ossowski S, Schroeder C, Schaaf CP, Malek N, Schirmacher… See abstract for full author list ➔ Menzel M, et al. Among authors: kazdal d. Eur J Cancer. 2024 Nov;211:114306. doi: 10.1016/j.ejca.2024.114306. Epub 2024 Sep 8. Eur J Cancer. 2024. PMID: 39293347 Free article.
Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study.
Dernbach G, Kazdal D, Ruff L, Alber M, Romanovsky E, Schallenberg S, Christopoulos P, Weis CA, Muley T, Schneider MA, Schirmacher P, Thomas M, Müller KR, Budczies J, Stenzinger A, Klauschen F. Dernbach G, et al. Among authors: kazdal d. Eur J Cancer. 2024 Nov;211:114292. doi: 10.1016/j.ejca.2024.114292. Epub 2024 Aug 23. Eur J Cancer. 2024. PMID: 39276594 Free article.
Tumour mutational burden: clinical utility, challenges and emerging improvements.
Budczies J, Kazdal D, Menzel M, Beck S, Kluck K, Altbürger C, Schwab C, Allgäuer M, Ahadova A, Kloor M, Schirmacher P, Peters S, Krämer A, Christopoulos P, Stenzinger A. Budczies J, et al. Among authors: kazdal d. Nat Rev Clin Oncol. 2024 Oct;21(10):725-742. doi: 10.1038/s41571-024-00932-9. Epub 2024 Aug 27. Nat Rev Clin Oncol. 2024. PMID: 39192001 Review.
High success rate of first proficiency testing for RET fusions and RET mutations in lung and thyroid cancer samples by various methods.
Siebolts U, Pappesch R, Bauer M, Dietmaier W, Ernst M, Haak A, Hartmann N, Ilm K, Kalbourtzis S, Krause T, Kazdal D, Schorle H, Utpatel K, Merkelbach-Bruse S. Siebolts U, et al. Among authors: kazdal d. Virchows Arch. 2024 Sep;485(3):519-526. doi: 10.1007/s00428-024-03890-w. Epub 2024 Aug 9. Virchows Arch. 2024. PMID: 39120655
KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.
Budczies J, Romanovsky E, Kirchner M, Neumann O, Blasi M, Schnorbach J, Shah R, Bozorgmehr F, Savai R, Stiewe T, Peters S, Schirmacher P, Thomas M, Kazdal D, Christopoulos P, Stenzinger A. Budczies J, et al. Among authors: kazdal d. Br J Cancer. 2024 Aug;131(3):524-533. doi: 10.1038/s41416-024-02746-z. Epub 2024 Jun 12. Br J Cancer. 2024. PMID: 38866964 Free PMC article.
Corrigendum to "First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations" [Eur J Cancer 199 (2024) 113556].
Blasi M, Kuon J, Lüders H, Misch D, Kauffmann-Guerrero D, Hilbrandt M, Kazdal D, Falkenstern-Ge RF, Hackanson B, Dintner S, Faehling M, Kirchner M, Volckmar AL, Kopp HG, Allgäuer M, Grohé C, Tufman A, Reck M, Frost N, Stenzinger A, Thomas M, Christopoulos P. Blasi M, et al. Among authors: kazdal d. Eur J Cancer. 2024 Jul;205:114130. doi: 10.1016/j.ejca.2024.114130. Epub 2024 May 24. Eur J Cancer. 2024. PMID: 38789333 No abstract available.
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H; PRIME-ROSE Consortium and the PCM4EU Consortium. Taskén K, et al. Acta Oncol. 2024 May 23;63:385-391. doi: 10.2340/1651-226X.2024.34791. Acta Oncol. 2024. PMID: 38779910 Free PMC article.
107 results